(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Taysha Gene Therapies's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast TSHA's revenue for 2023 to be $467,692,685, with the lowest TSHA revenue forecast at $404,001,558, and the highest TSHA revenue forecast at $531,383,811. On average, 2 Wall Street analysts forecast TSHA's revenue for 2024 to be $3,744,975,803, with the lowest TSHA revenue forecast at $933,512,101, and the highest TSHA revenue forecast at $6,556,439,505.
In 2025, TSHA is forecast to generate $6,985,730,187 in revenue, with the lowest revenue forecast at $1,448,036,496 and the highest revenue forecast at $12,523,423,877.